PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA

Area of Science:

• Pediatric Oncology
• Infectious Disease Management
• Pharmacology

Background:

• Febrile neutropenia (FN) is a frequent and serious complication in pediatric cancer patients undergoing chemotherapy.
• Effective management of FN is crucial to prevent severe infections and treatment interruptions.

Purpose of the Study:

• To compare the clinical efficacy of continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in pediatric patients with febrile neutropenia.
• To determine if one infusion method offers superior outcomes in this vulnerable patient population.

Main Methods:

• A non-blinded randomized controlled trial was conducted with hemato-oncological pediatric patients diagnosed with FN.
• Patients were randomized to receive either intermittent intravenous TZP infusion (Group 1) or continuous intravenous TZP infusion (Group 2).
• Treatment efficacy was assessed by comparing treatment failure rates, fever resolution, clinical cure, and mortality between the two groups.

Main Results:

• A total of 176 episodes of FN were assessed (100 in the intermittent group, 76 in the continuous group).
• No statistically significant difference in treatment failure was observed between continuous (21%) and intermittent (13%) TZP infusion (p = 0.15).
• Mortality rates were low and similar, with one death in each group.

Conclusions:

• Both continuous and intermittent infusion of piperacillin/tazobactam demonstrated comparable clinical efficacy in managing febrile neutropenia in pediatric cancer patients.
• There were no significant differences in fever resolution, clinical cure rates, or overall mortality between the two administration methods.
• The findings suggest flexibility in choosing TZP infusion methods for pediatric FN based on clinical context and resource availability.